Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07570940 · ClinicalTrials.gov registry record · Phase 4
A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery
A Phase 4 study, sponsored by Mayo Clinic.
- Not yet
- Registry status
- Phase 4
- Development phase
- 450
- Enrollment target
NCT07570940: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT07570940 is a Phase 4 study that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 450 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07570940, a Phase 4 study, has not yet begun recruiting, sponsored by Mayo Clinic.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 450 participants
- Enrollment target
Study Summary
The purpose of this study is assess the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients who receive pre-surgical stellate ganglion blockade with liposomal bupivacaine, compared to those receiving a saline placebo, using continuous electrocardiographic monitoring via wearable ECG devices.
Interventions
- DRUG Placebo
- DRUG Liposomal bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2026-06 |
| Est. Completion | 2030-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07570940
The ClinicalTrials.gov registry entry for NCT07570940 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07570940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07570940 about?
NCT07570940 is a clinical study titled "A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery". The purpose of this study is assess the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients who receive pre-surgical stellate ganglion blockade with liposomal bupivacaine, compared to those receiving a saline placebo, using continuous electrocardiographic mon...
What is the current status of trial NCT07570940?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 450 participants. The study started on 2026-06. Estimated completion is 2030-06.
What interventions are being tested in trial NCT07570940?
The interventions under investigation include: Placebo (DRUG), Liposomal bupivacaine (DRUG).
Who is sponsoring clinical trial NCT07570940?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.